Biology Reference
In-Depth Information
46. Czauderna F, Fechtner M, Dames S, Aygun H, Klippel A, Pronk GJ et al (2003) Structural
variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic
Acids Res 31(11):2705-2716
47. Harborth J, Elbashir SM, Vandenburgh K, Manninga H, Scaringe SA, Weber K et al (2003)
Sequence, chemical, and structural variation of small interfering RNAs and short hairpin
RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev
13(2):83-105
48. Choung S, Kim YJ, Kim S, Park HO, Choi YC (2006) Chemical modification of siRNAs to
improve serum stability without loss of efficacy. Biochem Biophys Res Commun
342(3):919-927
49. Allerson CR, Sioufi N, Jarres R, Prakash TP, Naik N, Berdeja A et al (2005) Fully 2'-modified
oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified
small interfering RNA. J Med Chem 48(4):901-904
50. Prakash TP, Allerson CR, Dande P, Vickers TA, Sioufi N, Jarres R et al (2005) Positional
effect of chemical modifications on short interference RNA activity in mammalian cells.
J Med Chem 48(13):4247-4253
51.Kraynack BA, Baker BF (2006) Small interfering RNAs containing full
2'-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent
activity. RNA 12(1):163-176
52. Layzer JM, McCaffrey AP, Tanner AK, Huang Z, Kay MA, Sullenger BA (2004) In vivo
activity of nuclease-resistant siRNAs. RNA 10(5):766-771
53. Morrissey DV, Blanchard K, Shaw L, Jensen K, Lockridge JA, Dickinson B et al (2005)
Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication.
Hepatology 41(6):1349-1356
54. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W et al (2005) Potent
and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol
23(8):1002-1007
55. Swayze EE, Siwkowski AM, Wancewicz EV, Migawa MT, Wyrzykiewicz TK, Hung G et al
(2007) Antisense oligonucleotides containing locked nucleic acid improve potency but cause
significant hepatotoxicity in animals. Nucleic Acids Res 35(2):687-700
56. Elmen J, Thonberg H, Ljungberg K, Frieden M, Westergaard M, Xu Y et al (2005) Locked
nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic
Acids Res 33(1):439-447
57. Elmen J, Lindow M, Silahtaroglu A, Bak M, Christensen M, Lind-Thomsen A et al (2008)
Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to
up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res
36(4):1153-1162
58. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S et al (2008) LNA-mediated
microRNA silencing in non-human primates. Nature 452(7189):896-899
59. Kubo T, Zhelev Z, Ohba H, Bakalova R (2007) Modi fi ed 27-nt dsRNAs with dramati-
cally enhanced stability in serum and long-term RNAi activity. Oligonucleotides 17(4):
445-464
60. Kubo T, Zhelev Z, Ohba H, Bakalova R (2008) Chemically modified symmetric and asym-
metric duplex RNAs: an enhanced stability to nuclease degradation and gene silencing effect.
Biochem Biophys Res Commun 365(1):54-61
61. Turner JJ, Jones SW, Moschos SA, Lindsay MA, Gait MJ (2007) MALDI-TOF mass spectral
analysis of siRNA degradation in serum confirms an RNAse A-like activity. Mol Biosyst
3(1):43-50
62. Collingwood MA, Rose SD, Huang L, Hillier C, Amarzguioui M, Wiiger MT et al (2008)
Chemical modification patterns compatible with high potency dicer-substrate small interfer-
ing RNAs. Oligonucleotides 18(2):187-200
63. Nishina K, Unno T, Uno Y, Kubodera T, Kanouchi T, Mizusawa H et al (2008) Efficient
in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol Ther
16(4):734-740
Search WWH ::
Custom Search